Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleBEHAVIORAL PHARMACOLOGY

Effects of N-Substituted Analogs of Benztropine: Diminished Cocaine-Like Effects in Dopamine Transporter Ligands

Jonathan L. Katz, Theresa A. Kopajtic, Gregory E. Agoston and Amy Hauck Newman
Journal of Pharmacology and Experimental Therapeutics May 2004, 309 (2) 650-660; DOI: https://doi.org/10.1124/jpet.103.060525
Jonathan L. Katz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Theresa A. Kopajtic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregory E. Agoston
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amy Hauck Newman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Previous studies demonstrated that analogs of benztropine (BZT) possess high affinity for the dopamine transporter, inhibit dopamine uptake, but generally have behavioral effects different from those of cocaine. One hypothesis is that muscarinic-M1 receptor actions interfere with cocaine-like effects. Several tropane-nitrogen substitutions of 4′,4′′-diF-BZT have reduced M1 affinity compared with the CH3-analog (AHN 1-055; 3α-[bis-(4-fluorophenyl)methoxy]tropane). All of the compounds displaced [3H]WIN 35,428 (2β-carbomethoxy-3β-(4-fluorophenyl)tropane) binding with affinities ranging from 11 to 108 nM. Affinities at norepinephrine ([3H]nisoxetine) and serotonin ([3H]citalopram) transporters ranged from 457 to 4810 and 376 to 3260 nM, respectively, and at muscarinic M1 receptors ([3H]pirenzepine) from 11.6 (AHN 1-055) to higher values, reaching 1030 nM for the other BZT-analogs. Cocaine and AHN 1-055 produced dose-related increases in locomotor activity in mice, with AHN 1-055 less effective than cocaine. The other compounds were ineffective in stimulating activity. In rats discriminating cocaine (29 μmol/kg i.p.) from saline, WIN 35,428 fully substituted for cocaine, whereas AHN 1-055 produced a maximal substitution of 79%. None of the other analogs fully substituted for cocaine. WIN 35,428 produced dose-related leftward shifts in the cocaine dose-effect curve, whereas selected BZT analogs produced minimal changes in the effects of cocaine. The results suggest that reducing M1 affinity of 4′,4′′-diF-BZT with N-substitutions reduces effectiveness in potentiating the effects of cocaine. Furthermore, although the BZT-analogs bind with high affinity at the dopamine transporter, their behavioral effects differ from those of cocaine. These compounds have reduced efficacy compared with cocaine, a long duration of action, and may serve as leads for the development of medications to treat cocaine abuse.

Footnotes

  • Portions of this research were presented at the 1999 Annual Meeting of the College on Problems of Drug Dependence.

  • Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.

  • DOI: 10.1124/jpet.103.060525.

  • ABBREVIATIONS: BZT, benztropine; 4′-Cl-BZT, 4′-chloro-3α-(diphenylmethoxy)tropane; LED, light-emitting diode; FR, fixed ratio; C, cocaine; S, saline; ANOVA, analysis of variance; 5-HT, 5-hydroxytryptamine; CL, confidence limit; AHN 1-055, 3α-[bis-(4-fluorophenyl)methoxy]tropane; AHN 2-005, N-allyl-3α-[bis-(4-fluorophenyl)methoxy]tropane; GA-I-103, N-(phenyl-n-butyl)-3α-[bis-(4-fluorophenyl)methoxy]tropane; JHW 005, N-benzyl-3α-[bis-(4-fluorophenyl)methoxy]tropane; JHW 007, N-(n-butyl)-3α-[bis-(4-fluorophenyl)methoxy]tropane; GBR 12909, 1-{2-[bis-(4-fluorophenyl)methoxy]ethyl}-4-(3-phenylpropyl)piperazine; WIN 35,428, 2β-carbomethoxy-3β-(4-fluorophenyl)tropane; BMY 14802, α-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine.

  • ↵1 Current address: EntreMed, Inc., 9640 Medical Center Dr., Rockville, MD 20850.

    • Received September 25, 2003.
    • Accepted December 3, 2003.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 309 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 309, Issue 2
1 May 2004
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Effects of N-Substituted Analogs of Benztropine: Diminished Cocaine-Like Effects in Dopamine Transporter Ligands
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleBEHAVIORAL PHARMACOLOGY

Effects of N-Substituted Analogs of Benztropine: Diminished Cocaine-Like Effects in Dopamine Transporter Ligands

Jonathan L. Katz, Theresa A. Kopajtic, Gregory E. Agoston and Amy Hauck Newman
Journal of Pharmacology and Experimental Therapeutics May 1, 2004, 309 (2) 650-660; DOI: https://doi.org/10.1124/jpet.103.060525

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleBEHAVIORAL PHARMACOLOGY

Effects of N-Substituted Analogs of Benztropine: Diminished Cocaine-Like Effects in Dopamine Transporter Ligands

Jonathan L. Katz, Theresa A. Kopajtic, Gregory E. Agoston and Amy Hauck Newman
Journal of Pharmacology and Experimental Therapeutics May 1, 2004, 309 (2) 650-660; DOI: https://doi.org/10.1124/jpet.103.060525
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Behavioral Battery for Testing Candidate Analgesics II
  • Behavioral Battery for Testing Candidate Analgesics in Mice I
  • MCAM Reverses and Prevents Fentanyl Ventilatory Depression
Show more Behavioral Pharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics